[{"id":"86f9c64d-1651-4e31-9eb5-ba7b981994da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05754853","created_at":"2023-03-06T15:01:34.107Z","updated_at":"2024-07-02T16:35:50.638Z","phase":"Phase 3","brief_title":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","source_id_and_acronym":"NCT05754853","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • pemetrexed • trastuzumab vedotin (MRG002)"],"overall_status":"Recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-04-13"},{"id":"cb5f0a13-9010-4f0f-b98d-0a3a22f7a485","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263869","created_at":"2022-03-03T14:06:09.167Z","updated_at":"2024-07-02T16:35:59.747Z","phase":"Phase 2","brief_title":"A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients","source_id_and_acronym":"NCT05263869","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • trastuzumab vedotin (MRG002)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2022-12-02"},{"id":"1b9cb10e-2252-4335-9ece-a59479724513","acronym":"","url":"https://clinicaltrials.gov/study/NCT05338957","created_at":"2022-04-21T14:55:36.910Z","updated_at":"2024-07-02T16:35:59.801Z","phase":"Phase 1/2","brief_title":"A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.","source_id_and_acronym":"NCT05338957","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab) • trastuzumab vedotin (MRG002)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/05/2022","start_date":" 08/05/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-12-01"},{"id":"0f798018-dc26-4e5b-b360-161bf1634c11","acronym":"","url":"https://clinicaltrials.gov/study/NCT04492488","created_at":"2021-01-18T21:34:54.392Z","updated_at":"2024-07-02T16:36:10.864Z","phase":"Phase 1/2","brief_title":"A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT04492488","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab vedotin (MRG002)"],"overall_status":"Recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2022-05-06"},{"id":"e245e0c8-6a4a-4a6c-8d84-8de0c078957d","acronym":"MRG002-006","url":"https://clinicaltrials.gov/study/NCT04839510","created_at":"2021-04-09T16:56:16.230Z","updated_at":"2024-07-02T16:36:19.540Z","phase":"Phase 2","brief_title":"A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer","source_id_and_acronym":"NCT04839510 - MRG002-006","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab vedotin (MRG002)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 09/01/2022","study_completion_date":" 09/01/2022","last_update_posted":"2021-12-14"},{"id":"de15564d-f12b-4f39-bde5-c151699835a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04837508","created_at":"2021-04-08T12:52:29.307Z","updated_at":"2024-07-02T16:36:19.652Z","phase":"Phase 2","brief_title":"A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer","source_id_and_acronym":"NCT04837508","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab vedotin (MRG002)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2021-12-10"},{"id":"b49bab44-dff6-4326-9abd-00223a51ecbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04941339","created_at":"2021-06-28T17:52:33.039Z","updated_at":"2024-07-02T16:36:19.874Z","phase":"Phase 1","brief_title":"A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04941339","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab vedotin (MRG002)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 11/21/2018","start_date":" 11/21/2018","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2021-12-03"},{"id":"0c8898a3-86d1-45a5-805a-c075abff3bcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05141786","created_at":"2021-12-02T18:54:32.365Z","updated_at":"2024-07-02T16:36:19.957Z","phase":"Phase 2","brief_title":"A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).","source_id_and_acronym":"NCT05141786","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab vedotin (MRG002)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-12-02"}]